|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT Registry显示文摘 | Gary R. Lichtenstein Brian G. Feagan Russell D. Cohen Bruce A. Salzberg Robert H. Diamond Donny M. Chen Michelle L. Pritchard William J. Sandborn | 2006 | Clinical Gastroenterology and Hepatology2006，，5： | 2 |
| 2 | Practice Parameters for the Treatment of Perianal Abscess and Fistula-in-Ano ?(Revised)显示文摘 | Mark H. Whiteford M.D. John Kilkenny M.D. Neil Hyman M.D. W. Donald Buie M.D. Jeffrey Cohen M.D. Charles Orsay M.D. Gary Dunn M.D. W. Brian Perry M.D. C. Neal Ellis M.D. Jan Rakinic M.D. Sharon Gregorcyk M.D. Paul Shellito M.D. Richard Nelson M.D. Joe J. | 2005 | Diseases of the Colon & Rectum2005，，7： | 2 |
| 3 | Protecting the delivery of heart failure: Regenerative Medicine/Stem Cell Therapeutics:Potential protections afforded by the Department of Health and Human Services and Health Resources Service Administration’s Bureau of Special Programs显示文摘Advances in stem cell science and potential clinical applications have brought clinical medicine closer to the actualization of Regenerative Medicine—an extension of transplantation of organs and cells and implantation of bioprosthetics and biodevices. The goal of such therapeutics will be intervention prior to onset of severe individual disability, enhance organ function and enhance patient performance status without incurring the economic impacts of standard organ transplantation. Regenerative Medicine is already demonstrating proof of principle or efficacy in restora- tion of myocardial contractility, joint mobility and function, immune competence, pulmonary function, immunologic self- tolerance, motor function and normal hemoglobin production with the next targets—diabetes mellitus (type I and type II), neurologic injury, hepatic dysfunction preparing to enter trials. Expenditures on health care needs of an aging U.S. citizenry approximate 20-25% ($3 trillion) of U.S. GDP currently and may to grow to 40% of U.S. GDP by 2025. As the potential of Regenerative Medicine is clinically realized, the societal impact and economic benefits will be disproportionately magnified in the economies of industrialized nations. The experi- ence of the Department of Health and Human Services (HHS), United Network for Organ Sharing (UNOS), the National Bone Marrow Donor Registry (NBMDR), and the National Vaccine Injury Compensation Programs (NVICP) can help ensure that as Regenerative Medicine strives to achieve clinical benefits while avoiding decimation of therapeutic options by product liability and medical malpractice concerns—concerns that crippled the U.S. vaccine manufacturing industry until the creation of the NVICP. The first 50 years of organ/cell/tissue transplantation demonstrates that clinical reality of allogeneic and autologous transplantation can antedate complete understanding of the basic science underlying successful transplantation. Product liability and medical malpractice liability have not impeded the development and growth of organ/cell/tissue transplanta- tion despite increased risks of infection, malignancy and cardiovascular disease in transplant recipients. Currently, human transplantation is only performed using FDA/CBER-approved, non-embryonic stem cells from peripheral blood, bone marrow or umbilical cord blood. Federal legislation passed in 2005 (HR2520 and S1317: The Bone Marrow and Cord Blood Cell Transplantation Program) authorizes the Secretary of Health and Human Services acting through the Director of HRSA to ensure uniform stem cell units distribution and outcomes monitoring via the federally-designated C.W. Bill Young Cell Transplant Program. Historically in the U.S., human biological therapies (vaccines, organ transplant and stem cell transplant) have re- quired federal protections to ensure continued distribution, fair access and avoidance of inhibitory product liability via protections afforded under the “stewardship” of the Secretary of Health and Human Services. The National Childhood Vaccine Injury Act of 1986 established the NVICP to equitably and expeditiously compensate individuals, or families of individuals, who have been declared injured by vaccines, thereby stabilizing a once imperiled vaccine supply by substan-tially reducing the threat of liability for vaccine companies, physicians, and other health care professionals who administer vaccines. Vaccines were the first biologics administered to U.S. citizens en masse and presage stem cell therapeutics (which may similarly be administered to millions) will similarly necessitate that a Stem Cell Injury Compensation Program (SCICP) will also need to be in place to demonstrate an intention to do good, an understanding that industry may do well, but that the health care consumer has a right of protection—all recognized from the outset. The Federal Tort Claims Act (FTCA) addresses liability claims via the Executive, Judicial and Legislative branches of Government, providing an um- brella of liability protection to other participants in the stem cell unit “chain of custody” under the FTCA—similar to the protection from product liability seen in organ and stem cell transplantation for the past 40-50 years. Efficacious development of regenerative medicine capabilities will mandate controlled access must first be provided for individuals with life-threatening diseases without therapeutic options or unable to benefit from or receive proven therapeutic options (ALS, cardiomyopathy and deemed not a candidate for heart transplantation, IDDM with hypoglyce- mic unawareness and no allogeneic source of traditional islet cell replacement available via HRSA) and mandates the prompt adoption of business and legal principles to ensure that the fate of the vaccine manufacturing industry does not become the fate of the stem cell therapeutics industry. If legal and regulatory concerns consume an increasing percentage of health care dollars that could be focused upon innovation, the Regenerative Medicine model will have not realized its full potential. The Diabetes Transplantation/Regenerative Medicine Model is the first organ to cell transplant model outside of oncology to demonstrate the regenerative medicine paradigm. Since all human tissues can be already recapitulated by human stem cells and key patent holders already exist, outlet or distribution of “more-than-minimally-manipulated stem cell units” as an IND approved under FDA/CBER guidelines can be accomplished via the current HHS/HRSA/Dept of Trans- plant methodology. As cardiovascular stem cell researchers develop human therapeutics utilizing more-than-minimally- manipulated stem cell products, they could be afforded protections from product liability historically enjoyed by the transplant community. Extending the Diabetes Transplant/Regenerative Medicine Model to the more than 5 million Americans with chronic heart failure, cell-based therapies to regenerate myocardial contractility could fill an existing void and be delivered in conjunction with and consistent with existing distribution of organs and tissues via HRSA/Department of Transplantation. | Gary S Friedman John S. Tomicki Neil Cohen Robert Marshal Philip Lowry Jeffrey Warsh | 2006 | Journal of Geriatric Cardiology2006，3，3： | 2 |
| 4 | LIGHT, a New Member of the TNF Superfamily, and Lymphotoxin α Are Ligands for Herpesvirus Entry Mediator显示文摘 | Davide N Mauri Reinhard Ebner Rebecca I Montgomery Kristine D Kochel Timothy C Cheung Guo-Liang Yu Steve Ruben Marianne Murphy Roselyn J Eisenberg Gary H Cohen Patricia G Spear Carl F Ware | 1998 | Immunity1998，，： | 1 |
| 5 | A key circu-latory defence against asphyxia in infancy – the heart of the mat-ter! 显示文摘 | Gary Cohen Miriam Katz-Salamon Girvan Malcolm | 2012 | J Physiol2012，590，23： | 1 |
| 6 | Effects of herpes simplex virus type 2 glycoprotein vaccines and CLDC adjuvant on genital herpes infection in the guinea pig显示文摘 | David I. Bernstein Julie D. Earwood Fernando J. Bravo Gary H. Cohen Roselyn J. Eisenberg Jennifer R. Clark Jeffrey Fairman Rhonda D. Cardin | 2011 | Vaccine2011，，11： | 1 |
| 7 | A Population-Based Study of Maternal and Perinatal Outcomes Associated with Assisted Reproductive Technology in Massachusetts显示文摘 | Laura A. Schieve Bruce Cohen Angela Nannini Cynthia Ferre Meredith A. Reynolds Zi Zhang Gary Jeng Maurizio Macaluso Victoria C. Wright | 2007 | Maternal and Child Health Journal2007，，6： | 1 |
| 8 | Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis显示文摘 | Alain Bitton Mark A. Peppercorn Donald A. Antonioli John L. Niles Samir Shah Athos Bousvaros Bernard Ransil Gary Wild Albert Cohen Michael D. deB Edwardes Anthony C. Stevens | 2001 | Gastroenterology2001，，1： | 1 |
| 9 | Practice Parameters for the Treatment of Perianal Abscess and Fistula-in-Ano ?(Revised)显示文摘 | Mark H. Whiteford John Kilkenny Neil Hyman W. Donald Buie Jeffrey Cohen Charles Orsay Gary Dunn W. Brian Perry C. Neal Ellis Jan Rakinic Sharon Gregorcyk Paul Shellito Richard Nelson Joe J. Tjandra Graham Newstead | 2005 | Diseases of the Colon & Rectum2005，，7： | 1 |
| 10 | Health-Related Quality of Life After Carotid Stenting Versus Carotid Endarterectomy显示文摘 | David J. Cohen Joshua M. Stolker Kaijun Wang Elizabeth A. Magnuson Wayne M. Clark Bart M. Demaerschalk Albert D. Sam James R. Elmore Fred A. Weaver Herbert D. Aronow Larry B. Goldstein Gary S. Roubin George Howard Thomas G. Brott | 2011 | Journal of the American College of Cardiology2011，，15： | 1 |
| 11 | Oxyntomodulin Suppresses Appetite and Reduces Food Intake in Humans显示文摘 | Mark A. Cohen Sandra M. Ellis Carel W. Le Roux Rachel L. Batterham Adrian Park Michael Patterson Gary S. Frost Mohammad A. Ghatei Stephen R. Bloom | 2003 | The Journal of Clinical Endocrinology & Metabolism2003，，10： | 1 |
| 12 | Psychological distress, social support, and disease activity in patients with inflammatory bowel disease显示文摘 | Maida J Sewitch Michal Abrahamowicz Alain Bitton Donald Daly Gary E Wild Albert Cohen Saul Katz Peter L Szego Patricia L Dobkin | 2001 | The American Journal of Gastroenterology2001，，5： | 1 |
| 13 | Hydrothermal oxidation of Navy excess hazardous materials显示文摘 | Dan Jensen Gary Lee | 1998 | Waste Management1998，18，： | 1 |
| 14 | Adaptive optics based on analog parallel stochastic optimization: analysis and experimental demonstration显示文摘 | Mikhail A Vorontsov Gary W Carhart Marc Cohen | 2000 | J Opt Soc Am A2000，17，8： | 1 |
| 15 | Practice Parameters for the Treatment of Perianal Abscess and Fistula-in-Ano ?(Revised)显示文摘 | Mark H. Whiteford M.D. John Kilkenny M.D. Neil Hyman M.D. W. Donald Buie M.D. Jeffrey Cohen M.D. Charles Orsay M.D. Gary Dunn M.D. W. Brian Perry M.D. C. Neal Ellis M.D. Jan Rakinic M.D. Sharon Gregorcyk M.D. Paul Shellito M.D. Richard Nelson M.D. Joe J. | 2005 | Diseases of the Colon & Rectum2005，，7： | 1 |
| 16 | Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis显示文摘 | Alain Bitton Mark A. Peppercorn Donald A. Antonioli John L. Niles Samir Shah Athos Bousvaros Bernard Ransil Gary Wild Albert Cohen Michael D. deB Edwardes Anthony C. Stevens | 2001 | Gastroenterology2001，，1： | 1 |
| 17 | Cytotoxicity of nimbolide, epoxyazadiradione and other limonoids from neem insecticide显示文摘 | Cohen Ephraim Quistad Gary B Casida John E | 1996 | Life Sciences Including Pharmacology Letters1996，58，23： | 1 |
| 18 | Evidence-based Guideline: Treatment of Painful Diabetic Neuropathy显示文摘 | Vera Bril John England Gary M. Franklin Miroslav Backonja Jeffrey Cohen David Del Toro Eva Feldman Donald J. Iverson Bruce Perkins James W. Russell Douglas Zochodne | 2011 | PM&R2011，，4： | 1 |
| 19 | ENERGY DOWN THE DRAIN-The Hidden Costs of California's Water Supply显示文摘 | Ronnie Cohen Barry Nelson Gary Wolff | 2004 | NATURAL RESOURCES DEFENSE COUNCIL2004，，8： | 1 |
| 20 | NON SPURIOUS SPECTRAL-LIKE ELEMENT METHODS FOR MAXWELL'S EQUATIONS显示文摘在这篇论文,我们给现状为所谓的“混合光谱元素”为麦克斯韦的方程。元素的几个家庭,例如边元素和不连续的 Galerkin,方法(DGM ) 被介绍并且讨论。特别地,我们显示出介绍一些数字驱散术语在这些方法避免假模式的需要。如此的术语为 DGM 是古典的,但是他们为边元素方法的使用是在这篇论文描述的一条新奇途径。最后,数字实验给这些元素的快、便宜的人物看。 | Gary Cohen Marc Duruflé | 2007 | Journal of Computational Mathematics2007，25，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员